This indicates that evaluation of MTAP expression by IHC at the conditions indicated above demonstrated 100% sensitivity (2/2) and 98% specificity (40/41) for evaluating CDKN2A status in meningiomas This result aligns with the findings of Sasaki et al., who reported that the loss of MTAP expression showed 100% sensitivity (5/5) and 100% specificity (24/24) for detecting CDKN2A homozygous deletion using the same anti-MTAP at the same dilution of 1:200 (10). The gene discussed is MTAP; the disease is meningioma.